Cargando…
Effects of orlistat combined with enzalutamide and castration through inhibition of fatty acid synthase in a PC3 tumor-bearing mouse model
Androgen deprivation therapy (ADT) is one of the typical treatments used for patients with prostate cancer (PCa). ADT, however, may fail when PCa develops castration-resistance. Fatty acid synthase (FASN), a critical enzyme involved in fatty acid synthesis, is found to be up-regulated in PCa. Since...
Autores principales: | Tyan, Yeu-Sheng, Lee, Yen-Po, Chuang, Hui-Yen, Wang, Wei-Hsun, Hwang, Jeng-Jong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Portland Press Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164108/ https://www.ncbi.nlm.nih.gov/pubmed/33974005 http://dx.doi.org/10.1042/BSR20204203 |
Ejemplares similares
-
Mechanism of Orlistat Hydrolysis by the Thioesterase
of Human Fatty Acid Synthase
por: Fako, Valerie E., et al.
Publicado: (2014) -
Synergistic Effect of Ginsenoside Rh2 Combines with Ionizing Radiation on CT26/luc Colon Carcinoma Cells and Tumor-Bearing Animal Model
por: Lee, Shan-Chih, et al.
Publicado: (2023) -
A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone
por: Graff, Julie N, et al.
Publicado: (2020) -
A combination of sorafenib and radiotherapy reduces NF-κB activity and growth of hepatocellular carcinoma in an orthotopic mouse model
por: Chuang, Hui-Yen, et al.
Publicado: (2021) -
A European, prospective, observational study of enzalutamide in patients with metastatic castration‐resistant prostate cancer: PREMISE
por: Payne, Heather, et al.
Publicado: (2021)